ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2021-4-4-40-45ojrdrt-207Research ArticleЯДЕРНАЯ МЕДИЦИНАNUCLEAR MEDICINEМетаболический объем опухоли при лимфомахMetabolic Tumor Volume for Patients with Lymphomashttps://orcid.org/0000-0002-0938-5213ВиноградоваЮ. Н.VinogradovaYu. N.

Виноградова Юлия Николаевна — д.м.н., руководитель отдела лучевых и комбинированных методов лечения, г.н.с., профессор кафедры радиологии, хирургии и онкологии

SPIN-код 288560 

197758, Санкт-Петербург, ул. Ленинградская, 70

70, Leningradskaya str., Pesochny, St. Petersburg, 197758

winogradova68@mail.ruhttps://orcid.org/0000-0002-8422-0689ИльинН. В.IlyinN. V.

Ильин Николай Васильевич — д.м.н., профессор, г.н.с. отдела фундаментальных исследований, профессор кафедры радиологии, хирургии и онкологии

197758, Санкт-Петербург, ул. Ленинградская, 70

70, Leningradskaya str., Pesochny, St. Petersburg, 197758

ilyin_prof@mail.ruhttps://orcid.org/0000-0003-2969-3480ТлостановаМ. С.TlostanovaM. S.

Тлостанова Марина Сергеевна — к.м.н., в.н.с. отдела лучевой диагностики, врач-радиолог отделения радиоизотопной позитронно-эмиссионной томографии

SPIN-код 3229-4643 

197758, Санкт-Петербург, ул. Ленинградская, 70

70, Leningradskaya str., Pesochny, St. Petersburg, 197758

tlostanovamarina@gmail.comhttps://orcid.org/0000-0002-9239-4814ИвановаА. А.IvanovaA. A.

Иванова Анна Александровна — к.м.н., заведующий отделением радиоизотопной позитронно-эмиссионной томографии, врач-радиолог

197758, Санкт-Петербург, ул. Ленинградская, 70

70, Leningradskaya str., Pesochny, St. Petersburg, 197758

anna-radiol@mail.ruРоссийский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова Минздрава РоссииРоссияA.M. Granov Russian Research Center of Radiology and Surgical TechnologiesRussian Federation202124112021444045Copyright © Виноградова Ю.Н., Ильин Н.В., Тлостанова М.С., Иванова А.А., 20212021Виноградова Ю.Н., Ильин Н.В., Тлостанова М.С., Иванова А.А.Vinogradova Y.N., Ilyin N.V., Tlostanova M.S., Ivanova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/207

При позитронно-эмиссионной томографии с 18F-ФДГ, совмещенной с рентгеновской компьютерной томографией (ПЭТ/КТ), применяют визуальный анализ ПЭТ-данных и оценку стандартного уровня накопления глюкозы. В последние годы разработаны волюметрические показатели, позволяющие оценивать метаболический объем опухоли при лимфомах и общий объем гликолиза в очагах поражения. В обзоре проведен анализ исследований по этой проблеме при разных видах лимфом с учетом возможного клинического значения указанных показателей и взаимосвязи их с известными факторами международного прогностического индекса.

Visual analysis of positron emission tomography/computed tomography (PET/CT) scans and semiquantitative parameter of glucose’s standardized uptake value are used in PET/CT with 18F-fluorodeoxyglucose (18F-FDG). Recently some volumetric parameters, which can evaluate metabolic tumor volume for patients with lymphomas and total lesion glycolysis in the tumor sites are established. In our study this problem was analyzed for different types of lymphomas considering clinical importance of these rates and their bond to known factors of international prognostic index.

лимфомыметаболический объем опухолиобщий объем гликолизаПЭТ/КТlymphomasmetabolic tumor volumetotal lesion glycolysisPET/CTРабота выполнена в рамках государственного задания Министерства здравоохранения Российской Федерации (тема № 121040200140-7).The work was carried out within the framework of the state assignment of the Ministry of Health of the Russian Federation (topic No. 121040200140-7).ReferencesПозитронная эмиссионная томография: Руководство для врачей. Под ред. А. М. Гранова и Л.А. Тютина. СПб.: Фолиант, 2008. 368 с. [Positron emission tomography. Guideline for doctors. Eds. A.M. Granov and L.A. Tytin. St.-Petersburg. 2008. 368 p (In Russian)].Позитронная эмиссионная томография: Руководство для врачей. Под ред. А. М. Гранова и Л.А. Тютина. СПб.: Фолиант, 2008. 368 с. [Positron emission tomography. Guideline for doctors. Eds. A.M. Granov and L.A. Tytin. St.-Petersburg. 2008. 368 p (In Russian)].Асланиди ИП, Мухортова ОВ, Катунина ТА и др. Современные аспекты применения позитронно-эмиссионной томографии при лимфомах. Клин. онкогематология. 2015;8(1):13-25. [Aslanidi IP, Mukhortova OV, Katynina TA, et al. Modern aspects of positron emission tomography for patients with lymphomas. Clinical Oncohematology. 2015;8(1):13-25 (In Russian)].Асланиди ИП, Мухортова ОВ, Катунина ТА и др. Современные аспекты применения позитронно-эмиссионной томографии при лимфомах. Клин. онкогематология. 2015;8(1):13-25. [Aslanidi IP, Mukhortova OV, Katynina TA, et al. Modern aspects of positron emission tomography for patients with lymphomas. Clinical Oncohematology. 2015;8(1):13-25 (In Russian)].Асланиди ИП, Мухортова ОВ, Катунина ТА и др. Клиническое применение позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, в онкогематологии — преимущества и ограничения. Вестник РОНЦ им. Н. Н. Блохина. 2016;27(4):49-60. [Aslanidi IP, Mukhortova OV, Katynina TA, et al. Clinical application of positron emission tomography/computed tomography in hematology — advantages and restrictions. Bulletin of the N.N. Blokhin RORC. 2016;27(4):49-60 (In Russian)].Асланиди ИП, Мухортова ОВ, Катунина ТА и др. Клиническое применение позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, в онкогематологии — преимущества и ограничения. Вестник РОНЦ им. Н. Н. Блохина. 2016;27(4):49-60. [Aslanidi IP, Mukhortova OV, Katynina TA, et al. Clinical application of positron emission tomography/computed tomography in hematology — advantages and restrictions. Bulletin of the N.N. Blokhin RORC. 2016;27(4):49-60 (In Russian)].Гележе ПВ, Морозов СП, Мандельблат ЮЭ и др. Современные критерии лучевой диагностики в оценке эффективности специального противоопухолевого лечения. Российский онкологический журнал. 2014(3):39-46 [Gelezhe PV, Morozov SP, Mandelblat YuA, et al. Modern criteria of X-ray diagnostics in evaluate of special cancer treatment’s efficiency. Russian Oncology Journal. 2014(3):39-46 (In Russian)].Гележе ПВ, Морозов СП, Мандельблат ЮЭ и др. Современные критерии лучевой диагностики в оценке эффективности специального противоопухолевого лечения. Российский онкологический журнал. 2014(3):39-46 [Gelezhe PV, Morozov SP, Mandelblat YuA, et al. Modern criteria of X-ray diagnostics in evaluate of special cancer treatment’s efficiency. Russian Oncology Journal. 2014(3):39-46 (In Russian)].Мухортова ОВ, Асланиди ИП, Ашрафян ЛА и др. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой у онкологических больных: методика обследования всего тела. Опухоли репродуктивной женской системы. 2009(3-4):70-7. [Mukhortova OV, Aslanidi IP, Ashrafyan LA, et al. Positron emission tomography/computed tomography with 18F-fluorodeoxyglucose by oncological patients: method of whole body’s examination. Tumors of Female’s Reproductive System. 2009(3-4):70-7 (In Russian)].Мухортова ОВ, Асланиди ИП, Ашрафян ЛА и др. Позитронно-эмиссионная томография с 18F-фтордезоксиглюкозой у онкологических больных: методика обследования всего тела. Опухоли репродуктивной женской системы. 2009(3-4):70-7. [Mukhortova OV, Aslanidi IP, Ashrafyan LA, et al. Positron emission tomography/computed tomography with 18F-fluorodeoxyglucose by oncological patients: method of whole body’s examination. Tumors of Female’s Reproductive System. 2009(3-4):70-7 (In Russian)].Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May;50 Suppl 1(Suppl 1):122S-50S. DOI: 10.2967/jnumed.108.057307.Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May;50 Suppl 1(Suppl 1):122S-50S. DOI: 10.2967/jnumed.108.057307.Ходжибекова ММ. Значение совмещенной позитронноэмиссионной и компьютерной томографии в диагностике и мониторинге лечения больных лимфомами. Автореф. дис. д-ра мед. наук. СПб. 2018. 50 с. [Hodzhibekova MM. The importance of positron emission tomography in diagnostics and monitoring survey of patients with lymphomas. Author’s abstract Dr. Sci. Med. St.-Petersburg. 2018. 50 p (In Russian)].Ходжибекова ММ. Значение совмещенной позитронноэмиссионной и компьютерной томографии в диагностике и мониторинге лечения больных лимфомами. Автореф. дис. д-ра мед. наук. СПб. 2018. 50 с. [Hodzhibekova MM. The importance of positron emission tomography in diagnostics and monitoring survey of patients with lymphomas. Author’s abstract Dr. Sci. Med. St.-Petersburg. 2018. 50 p (In Russian)].Michallet AS, Sesques P, Rabe KG, et al. An 18F-FDG-PET maximum standardized uptake value >10 represents novel valid marker for discerning Richter’s Syndrome. Leuk Lymphoma. 2016;57(6):1474-7. DOI: 10.3109/10428194.2015.1099643.Michallet AS, Sesques P, Rabe KG, et al. An 18F-FDG-PET maximum standardized uptake value >10 represents novel valid marker for discerning Richter’s Syndrome. Leuk Lymphoma. 2016;57(6):1474-7. DOI: 10.3109/10428194.2015.1099643.Hutchings M, Loft A, Hansen M, et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006 Sep;24(3):146-50. DOI: 10.1002/hon.782.Hutchings M, Loft A, Hansen M, et al. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006 Sep;24(3):146-50. DOI: 10.1002/hon.782.Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan associated with shorter survival in patients with diffuse large B cell lymphoma. Hematol. 2011 Apr;93(4):502-8. DOI: 10.1007/s12185-011-0822-y.Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan associated with shorter survival in patients with diffuse large B cell lymphoma. Hematol. 2011 Apr;93(4):502-8. DOI: 10.1007/s12185-011-0822-y.Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim 18F-EDG PFT SUV max reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014 Apr;55(4):569-73. DOI: 10.2967/jnumed.113.130609.Rossi C, Kanoun S, Berriolo-Riedinger A, et al. Interim 18F-EDG PFT SUV max reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med. 2014 Apr;55(4):569-73. DOI: 10.2967/jnumed.113.130609.Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUV max reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011 Jul 7;118(1):37-43. DOI: 10.1182/blood-2010-12-327767.Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUV max reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011 Jul 7;118(1):37-43. DOI: 10.1182/blood-2010-12-327767.Safar V, Dupuis J, Itti E, et al. Interim [18F] fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012 Jan 10;30(2):184-90. DOI: 10.1200/JCO.2011.38.2648.Safar V, Dupuis J, Itti E, et al. Interim [18F] fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol. 2012 Jan 10;30(2):184-90. DOI: 10.1200/JCO.2011.38.2648.Pregno P, Chiappella A, Bellö M. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012 Mar 1;119(9):2066-73. DOI: 10.1182/blood-2011-06-359943.Pregno P, Chiappella A, Bellö M. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012 Mar 1;119(9):2066-73. DOI: 10.1182/blood-2011-06-359943.Manot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of’ the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015 Aug 10;33(23):2523-9. DOI: 10.1200/JCO.2014.58.9846.Manot C, Klingbiel D, Hitz F, et al. Final results of a prospective evaluation of’ the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol. 2015 Aug 10;33(23):2523-9. DOI: 10.1200/JCO.2014.58.9846.Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for earlystage Hodgkin’s lymphoma. Cancer Sci. 2013 Dec;104(12):1656- 61. DOI: 10.1111/cas.12282.Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for earlystage Hodgkin’s lymphoma. Cancer Sci. 2013 Dec;104(12):1656- 61. DOI: 10.1111/cas.12282.Cottereau AS, Versari A, Loft A, et al. Patients with early-stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC/LYSA/FIL) trial. Hematol Oncology. 2017;35(S2):35-6.Cottereau AS, Versari A, Loft A, et al. Patients with early-stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC/LYSA/FIL) trial. Hematol Oncology. 2017;35(S2):35-6.Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43. DOI: 10.1007/s00259-014-2783-x.Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43. DOI: 10.1007/s00259-014-2783-x.Pike LC, Kirwood AA, Patrick P, et al. Can baseline PET/CT Features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033). Hematol Oncology. 2017;35(S2):37-8.Pike LC, Kirwood AA, Patrick P, et al. Can baseline PET/CT Features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033). Hematol Oncology. 2017;35(S2):37-8.Tseng D, Rachakonda IP, Su Z, et al. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin’s disease. Radiat Oncol. 2012 Jan 19;7:5. DOI: 10.1186/1748-717X-7-5.Tseng D, Rachakonda IP, Su Z, et al. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin’s disease. Radiat Oncol. 2012 Jan 19;7:5. DOI: 10.1186/1748-717X-7-5.Moskowitz AJ, Shoder H, Gavane S, et al. Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PETadapted salvage therapy with brentuximab vedotin and augmented ice. Hematol Oncology. 2017;35(S2):36-7. DOI: 10.1002/hon.2437_17.Moskowitz AJ, Shoder H, Gavane S, et al. Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PETadapted salvage therapy with brentuximab vedotin and augmented ice. Hematol Oncology. 2017;35(S2):36-7. DOI: 10.1002/hon.2437_17.Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ∆SUV max. Eur J Nucl Med Mol Imaging. 2013;40(9):1312-20. DOI: 10.1007/s00259-013-2435-6.Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ∆SUV max. Eur J Nucl Med Mol Imaging. 2013;40(9):1312-20. DOI: 10.1007/s00259-013-2435-6.Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B-cell lymphoma without extranodal site involvement. Ann Hematol. 2012 May;91(5):697-703. DOI: 10.1007/s00277-011-1357-2.Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B-cell lymphoma without extranodal site involvement. Ann Hematol. 2012 May;91(5):697-703. DOI: 10.1007/s00277-011-1357-2.Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B-cell lymphoma. Cancer Sci. 2012 Mar;103(3):477-82. DOI: 10.1111/j.1349-7006.2011.02164.x.Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B-cell lymphoma. Cancer Sci. 2012 Mar;103(3):477-82. DOI: 10.1111/j.1349-7006.2011.02164.x.Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumor volume and early response on PET/ CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19. DOI: 10.1007/s00259-016-3315-7.Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumor volume and early response on PET/ CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19. DOI: 10.1007/s00259-016-3315-7.Zhou M, Chen Y, Huang H, et al. Prognostic value of TLG of baseline FDG PET/CT in DLBCL. Oncotarget. 2016 Dec 13;7(50):83544-53. DOI: 10.18632/oncotarget.13180.Zhou M, Chen Y, Huang H, et al. Prognostic value of TLG of baseline FDG PET/CT in DLBCL. Oncotarget. 2016 Dec 13;7(50):83544-53. DOI: 10.18632/oncotarget.13180.Zhao P, Yu T, Pan Z. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumor volume (MTV) and further stratification in low-intermediate (L–I) and high- intermediate (H–I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med. 2021 Jan;35(1):24- 30. DOI: 10.1007/s12149-020-01531-1.Zhao P, Yu T, Pan Z. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumor volume (MTV) and further stratification in low-intermediate (L–I) and high- intermediate (H–I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med. 2021 Jan;35(1):24- 30. DOI: 10.1007/s12149-020-01531-1.Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumor volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22. DOI: 10.1007/s00259-014-2822-7.Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumor volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22. DOI: 10.1007/s00259-014-2822-7.Kim TM, Paeng JC, Chun LK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B-cell lymphoma. Cancer. 2013 Mar 15;119(6):1195-202. DOI: 10.1002/cncr.27855.Kim TM, Paeng JC, Chun LK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B-cell lymphoma. Cancer. 2013 Mar 15;119(6):1195-202. DOI: 10.1002/cncr.27855.Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015 Jun;94(6):532-9. DOI: 10.1111/ejh.12467.Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015 Jun;94(6):532-9. DOI: 10.1111/ejh.12467.Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/ CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014;92(5):382-9. DOI: 10.1111/ejh.12268.Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/ CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014;92(5):382-9. DOI: 10.1111/ejh.12268.Schoder H, Zelenetz AD, Hamlin P, et al. Prospective study of 3′-deoxy-3′ 18F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016 May;57(5):728-34. DOI: 10.2967/jnumed.115.166769.Schoder H, Zelenetz AD, Hamlin P, et al. Prospective study of 3′-deoxy-3′ 18F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016 May;57(5):728-34. DOI: 10.2967/jnumed.115.166769.Schoder H, Polley MY, Knopp MV. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: Results from GALGB-50303 clinical trial. Clinical Trial. Blood. 2020 Jun 18;135(25):2224-34. DOI: 10.1182/blood.2019003277.Schoder H, Polley MY, Knopp MV. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: Results from GALGB-50303 clinical trial. Clinical Trial. Blood. 2020 Jun 18;135(25):2224-34. DOI: 10.1182/blood.2019003277.Meignan M, Cottereau AS, Vesari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. J Clin Oncol. 2016 Oct 20;34(30):3618-26. DOI: 10.1200/JCO.2016.66.9440.Meignan M, Cottereau AS, Vesari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. J Clin Oncol. 2016 Oct 20;34(30):3618-26. DOI: 10.1200/JCO.2016.66.9440.Maior A, Hammes A, Schmidt MQ, et al. Evaluating novel PET/CT functional parameters TLG and TMTV in differentiating low grade vs Grade 3A follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):39-46. DOI: 10.1016/j.clml.2019.09.609.Maior A, Hammes A, Schmidt MQ, et al. Evaluating novel PET/CT functional parameters TLG and TMTV in differentiating low grade vs Grade 3A follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):39-46. DOI: 10.1016/j.clml.2019.09.609.Albano D, Camoni L, Guibbuni R, et al. Prognostic value of 18F-FDG PET/CT metabolic parameters in splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e897-e904. DOI: 10.1016/j.clml.2020.06.018.Albano D, Camoni L, Guibbuni R, et al. Prognostic value of 18F-FDG PET/CT metabolic parameters in splenic marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e897-e904. DOI: 10.1016/j.clml.2020.06.018.Okuyucu K, Ozaydın S, Alagozl E, et al. Prognosis estimation under the light of metabolic tumor parameters on initial FDGPET/ CT in patients with primary extranodal lymphoma. Radiol Oncol. 2016 Sep 8;50(4):360-9. DOI: 10.1515/raon-2016-0045.Okuyucu K, Ozaydın S, Alagozl E, et al. Prognosis estimation under the light of metabolic tumor parameters on initial FDGPET/ CT in patients with primary extranodal lymphoma. Radiol Oncol. 2016 Sep 8;50(4):360-9. DOI: 10.1515/raon-2016-0045.Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015 Aug 20;126(8):950-6. DOI: 10.1182/blood-2014-12-616474.Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015 Aug 20;126(8):950-6. DOI: 10.1182/blood-2014-12-616474.Алексеев СА, Крюков ЕВ, Троян ВН и др. Изменение объема активной опухоли методом ПЭТ/КТ с 18F-ФДГ — новый возможный критерий статуса заболевания у пациентов с множественной миеломой (первые результаты). Радиология — Практика. 2020;(5):6-17. [Alekseev SA, Kryukov EV, Troyan VN, et al. Variation of active neoplastic tissue’s volume due to 18F-FDG PET/CT — new possible criteria of multiplymyeloma patient’s status (first results). Radiology — Practice. 2020;(5):6-17 (In Russian)].Алексеев СА, Крюков ЕВ, Троян ВН и др. Изменение объема активной опухоли методом ПЭТ/КТ с 18F-ФДГ — новый возможный критерий статуса заболевания у пациентов с множественной миеломой (первые результаты). Радиология — Практика. 2020;(5):6-17. [Alekseev SA, Kryukov EV, Troyan VN, et al. Variation of active neoplastic tissue’s volume due to 18F-FDG PET/CT — new possible criteria of multiplymyeloma patient’s status (first results). Radiology — Practice. 2020;(5):6-17 (In Russian)].

The authors declare that there are no conflicts of interest present.